Patents Assigned to CorTechs
-
Patent number: 6001814Abstract: The present invention relates to certain substituted oxadiazole nonpeptides, which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.Type: GrantFiled: June 3, 1998Date of Patent: December 14, 1999Assignee: Cortech Inc.Inventors: Albert C. Gyorkos, Lyle W. Spruce
-
Patent number: 6001811Abstract: The present invention relates to oxadiazole, thiadiazole, and triazole peptoids that are inhibitors of serine protease, specifically human neutrophil elastase; which proteases are useful in treatment of adult respiratory distress syndrome, septic shock, and multiple organ failure.Type: GrantFiled: December 4, 1997Date of Patent: December 14, 1999Assignee: Cortech Inc.Inventors: Albert Gyorkos, Lyle W. Spruce
-
Patent number: 5998379Abstract: The present invention relates to certain substituted oxadiazole, thiadiazole, and triazole peptoids that are useful as inhibitors of serine proteases, in particular human neutrophil elastase. Serine protease inhibitors of the invention are useful in the treatment of, for example, adult respiratory distress syndrome, septic shock, and myocardial ischemia-reperfusion injury.Type: GrantFiled: December 4, 1997Date of Patent: December 7, 1999Assignee: Cortech Inc.Inventors: Albert Gyorkos, Lyle W. Spruce
-
Patent number: 5891852Abstract: The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.Type: GrantFiled: December 6, 1996Date of Patent: April 6, 1999Assignee: Cortech, Inc.Inventors: Albert Gyorkos, Lyle W. Spruce
-
Patent number: 5874585Abstract: The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases including human neutrophil elastase, equivalently known as human leukocyte elastase.Type: GrantFiled: August 15, 1996Date of Patent: February 23, 1999Assignee: Cortech, Inc.Inventors: Albert Gyorkos, Lyle W. Spruce
-
Patent number: 5869455Abstract: The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.Type: GrantFiled: December 6, 1996Date of Patent: February 9, 1999Assignee: Cortech, Inc.Inventors: Albert Gyorkos, Lyle W. Spruce
-
Patent number: 5863899Abstract: A bradykinin antagonist of the formula:(BKAn) (X) (Y)where BKAn is a bradykinin antagonist peptide; Y is a Pharmacophore; and X is a bridging link chemically joining the BKAn and Y components.Type: GrantFiled: August 29, 1994Date of Patent: January 26, 1999Assignee: Cortech, Inc.Inventors: John C. Cheronis, James K. Blodgett, Val Smith Goodfellow, Manoj Vinayak Marathe, Lyle W. Spruce, Eric T. Whalley
-
Patent number: 5861380Abstract: The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.Type: GrantFiled: December 6, 1996Date of Patent: January 19, 1999Assignee: Cortech, Inc.Inventors: Albert Gyorkos, Lyle W. Spruce
-
Patent number: 5849863Abstract: The present invention provides bradykinin antagonists effective to inhibit cancer cell growth. Also provided are methods of inhibiting lung cancer cell growth by administering a therapeutically effective amount of a dimerized bradykinin antagonist.Type: GrantFiled: September 8, 1995Date of Patent: December 15, 1998Assignees: University of Colorado, Cortech, Inc.Inventors: John M. Stewart, Daniel C. Chan, Eric T. Whalley, Lajos Gera
-
Patent number: 5843900Abstract: The present invention relates to pharmaceutically effective heterodimers comprising a bradykinin antagonist component covalently linked to a mu-opioid agonist component.Type: GrantFiled: June 5, 1995Date of Patent: December 1, 1998Assignee: Cortech, Inc.Inventors: John C. Cheronis, Albert Gyorkos, Lyle W. Spruce, Eric T. Whalley
-
Patent number: 5834431Abstract: The present invention provides des-Arg.sup.9 bradykinin analogs which are selective B1 receptor antagonists.Type: GrantFiled: September 8, 1995Date of Patent: November 10, 1998Assignees: Cortech, Inc., University of ColoradoInventors: John M. Stewart, Eric T. Whalley, Lajos Gera
-
Patent number: 5811241Abstract: The invention provides a method of synthesizing N-substituted 1,4-piperazines and N-substituted 1,4-piperazinediones. The invention also provides a method for synthesing combinatorial libraries of piperazine derivatives which can be assayed for biological activity in pre-specified ligand binding or enzymatic activity screens.Type: GrantFiled: September 13, 1995Date of Patent: September 22, 1998Assignee: Cortech, Inc.Inventors: Val S. Goodfellow, Donald A. McLeod, James Ivan Gerrity, Christopher P. Laudeman, Michael R. Burkard
-
Patent number: 5807829Abstract: The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.Type: GrantFiled: December 6, 1996Date of Patent: September 15, 1998Assignee: Cortech, Inc.Inventors: Albert Gyorkos, Lyle W. Spruce
-
Patent number: 5801148Abstract: The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.Type: GrantFiled: December 6, 1996Date of Patent: September 1, 1998Assignee: Cortech, Inc.Inventors: Albert Gyorkos, Lyle W. Spruce
-
Patent number: 5750506Abstract: Bradykinin antagonists, particularly Cys.sup.6 analogs, which have an extended hydrophobic side chain.Type: GrantFiled: May 13, 1996Date of Patent: May 12, 1998Assignee: Cortech, Inc.Inventors: Val S. Goodfellow, Heather B. Kroona, Eric T. Whalley, Francine E. Wincott, Dana A. Zummach
-
Patent number: 5722413Abstract: A medical demonstration apparatus (1) adapted for indicating cardiac exertion. The apparatus (1) comprises an elastically and recoverably defomable hollow bulb (3) in the shape of a heart. The bulb (3) is connected via a connector (4) nd the tube (5) to a manometer (2) which is used to indicate blood pressure. The bulb (3) is able to be squeezed to indicate the cardiac exertion required to reach a predetermined pressure as indicated on the manometer (2).Type: GrantFiled: August 30, 1996Date of Patent: March 3, 1998Assignee: CorTech Development Pty LtdInventors: Robert William Futcher, Graham Frederick Orr
-
Patent number: 5700779Abstract: The present invention provides bradykinin type peptides containing N-substituted glycines, particularly bradykinin antagonist peptides useful for the treatment of conditions mediated by bradykinin including pain and inflammation.Type: GrantFiled: June 20, 1996Date of Patent: December 23, 1997Assignee: Cortech, Inc.Inventors: Val S. Goodfellow, Manoj V. Marathe, Eric T. Whalley, Timothy D. Fitzpatrick, Karen G. Kuhlman
-
Patent number: 5663416Abstract: 2-Phenylalkanoate esters which are useful as inhibitors of human leukocyte elastase.Type: GrantFiled: April 5, 1995Date of Patent: September 2, 1997Assignee: Cortech Inc.Inventors: Gary P. Kirschenheuter, Lyle W. Spruce, John C. Cheronis
-
Patent number: 5635593Abstract: A brandykinin antagonist of the formula:X(BKA).sub.nwherein BKA is the peptide chain of a bradykinin antagonist peptide, X is a linking group and n is a whole number greater than 1. The BKA substituents may be the same or different. Monomeric antagonists of the formula X(BKA) are also disclosed. Also disclosed are bradykinin antagonists of the formula:(Y)(X)(BKA)where X and BKA have the meanings indicated above and Y is the peptide chain of an antagonist or agonist for a non-bradykinin receptor.Type: GrantFiled: May 12, 1995Date of Patent: June 3, 1997Assignee: Cortech, Inc.Inventors: John C. Cheronis, James K. Blodgett, Eric T. Whalley, Shadrach R. Eubanks, Lisa G. Allen, Khe T. Nguyen
-
Patent number: 5618792Abstract: The present invention relates to certain substituted oxadiazole, thiadiazole and triazole peptoids which are useful as inhibitors of serine proteases including human neutrophil elastase, equivalently known as human leukocyte elastase.Type: GrantFiled: November 21, 1994Date of Patent: April 8, 1997Assignee: Cortech, Inc.Inventors: Albert Gyorkos, Lyle W. Spruce